Sanofi Logo
  1. Home
  2. Home
  3. Dosing and Administration

Dosing and Administration

Mozobil is a subcutaneous injection indicated in combination with filgrastim to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin’s lymphoma (NHL) or multiple myeloma (MM).1

Dosage Forms and Strengths

Mozobil (plerixafor) injection (NDC Number 0024–5862–01) is provided as a 20 mg/mL solution in a single-dose vial. Each vial is filled to deliver a volume of 1.2 mL and contains 24 mg of drug and 5.9 mg sodium chloride dissolved in Water for Injection adjusted to a pH of 6.0–7.5 with hydrochloric acid and with sodium hydroxide, if required.1

Dosing Mozobil

The recommended dose of Mozobil by subcutaneous injection is based on actual body weight, not to exceed 40 mg/day.1

Recommended dose of Mozobil in patients with renal impairment (≤50 mL/min creatinine clearance)1

  • Patient weight ≤83 kg: 13-mg fixed dose or 0.16 mg/kg once daily
  • Patient weight >83 kg and <160 kg: 0.16 mg/kg once daily (not to exceed 27 mg/day)

Administering Mozobil

  • Begin treatment with Mozobil after the patient has received filgrastim once daily for 4 days1
  • Administer Mozobil approximately 11 hours prior to initiation of each apheresis session for up to 4 consecutive days1
  • Patients should be monitored for signs of hypersensitivity during and after Mozobil infusion for at least 30 minutes and until clinically stable. Anaphylactic shock and serious hypersensitivity reactions, some of which have been life-threatening, have occurred in patients receiving Mozobil. Observe patients for signs and symptoms of hypersensitivity during and after Mozobil administration for at least 30 minutes and until clinically stable. Only administer Mozobil when personnel and therapies are immediately available for the treatment of anaphylaxis and other hypersensitivity reactions1
Start Mozobil treatment after taking G-CSF once for 4 days and administer Mozobil 11 hours prior to each apheresis session for up to 4 consecutive days.

Pharmacodynamic Studies With Mozobil Demonstrating Peak Collection Time of CD34+ Cells

Peripheral CD34+ Cells Collected After Administration of Mozobil + Filgrastim2,*

The graph shows CD34+ cell counts over 24 hours following Mozobil administration
  • The 11-hour time point in the Mozobil Prescribing Information was chosen as the peak midpoint1
  • Sustained elevation in CD34+ cell count was observed from 4 to 18 hours after administration of Mozobil1,2
  • Mobilization and collection of peripheral CD34+ cells after administration of Mozobil + filgrastim peaked between 10 and 14 hours1,2

See the estimated percentage of patients that reached target counts by apheresis day.

Information for Patients Starting Mozobil

Before prescribing Mozobil, advise your patients of the following1:

  • The potential exists for anaphylactic reactions, including signs and symptoms such as urticaria, periorbital swelling, dyspnea, or hypoxia during and following Mozobil injection and to report these symptoms immediately to a healthcare professional
  • Inform a healthcare professional immediately if symptoms of vasovagal reactions such as orthostatic hypotension or syncope occur during or shortly after their Mozobil injection
  • Patients who experience itching, rash, or reaction at the site of the injection should notify a healthcare professional as these symptoms have been treated with over-the-counter medications during clinical trials
  • Mozobil may cause gastrointestinal disorders, including diarrhea, nausea, vomiting, flatulence, and abdominal pain. Patients should be told how to manage specific gastrointestinal disorders and to inform their healthcare professional if severe events occur following Mozobil injection
  • Female and males of reproductive potential should use effective contraceptive methods during Mozobil use and for one week after cessation of treatment
  • Breastfeeding is not recommended during treatment with Mozobil and for one week after the final dose

Support

Through Sanofi Patient Connection your patients can get assistance navigating the insurance process and more.

LEARN MORE ABOUT SANOFI PATIENT CONNECTION

About Mozobil

In clinical trials, Mozobil + Filgrastim was shown to significantly reduce mobilization failures. Learn more about the clinical trials.1,3,4

See the Details

Abbreviations: MM, multiple myeloma; NDC, National Drug Code; NHL, non-Hodgkin's lymphoma.

References:

  1. Mozobil [prescribing information]. Cambridge, MA: Genzyme Corporation; 2023.
  2. Liles WC, Rodger E, Broxmeyer HE, et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion. 2005;45(3):295-300.
  3. DiPersio JF, Micallef IN, Stiff PJ, et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin’s lymphoma. J Clin Oncol. 2009;27(28):4767-4773.
  4. DiPersio JF, Stadtmauer EA, Nademanee A, et al; for the 3102 Investigators. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood. 2009;113(23):5720-5726.